The clinical course of chronic lymphocytic leukemia (CLL) is highly variable, ranging from slow progression and survival for several decades to rapidly progressive and chemotherapyresistant disease with death within 1 year of diagnosis. The hierarchical model of common genomic aberrations determined by interphase fluorescence in situ hybridization (FISH) and the analysis of the mutational status of the immunoglobulin heavychain variable region genes (IGVH status) are broadly used molecular markers to predict the prognosis of CLL patients.
Despite the high prognostic value of IGVH status and FISH analysis, the clinical course of some patients defies the predictions. 1 Until now the presence of del(17p) or a TP53 mutation are the only established predictive markers for therapy response. 2 However, they are infrequent in newly diagnosed patients (del(17p): 4%; additional TP53 mutation: 1.1%), 3, 4 and sometimes misleading (overall survival (OS) rate 65% at 3 years in treatment-naïve patients). 1 Thus, a more accurate easy assessable risk classifier for CLL patients is desirable.
To improve our ability to predict the prognosis of CLL patients, gene expression profiling (GEP) and microRNA expression levels were used to develop prognostic scores. 5, 6 Calin et al. 6 reported a molecular signature of 13 microRNAs associated with the expression of ZAP70, the mutational status of IGVH, and the time between diagnosis and initial treatment. Rodriguez et al. 5 used a small custom oligonucleotide microarray to generate a prognostic model based on the expression of seven genes (including genes involved in Wnt and NF-kB signaling) for time to treatment (TTT) and validated this model in an independent CLL series. Although these studies provided new insights into the biology of CLL, all these signatures fell short of surpassing the traditional genetic markers in prognostic power; they were generated on small micro array platforms or were not validated using routine diagnostic techniques like real-time PCR (RT-PCR) orFmost importantlyFthey were not shown to predict overall survival.
Therefore, we set out to develop and validate a simple but powerful gene expression score (PS.8) that predicts survival in CLL patients by correlating the survival data of a large patient cohort with genome-wide gene expression data.
Peripheral Two patients were analyzed twice at different disease stages (151 microarrays from 149 patients). These two patients received therapy between their two analysis time points and were analyzed the second time at relapse. There were 2.5 and 3 years time gaps between these analysis time points. We chose to treat the two analysis results from each of these two patients as separate data points because of the disease evolution that had taken place. The validation cohort consisted of 149 additional patients (accrued from 2005 to 2007). Follow-up data from the time of diagnostic work-up (study entry) were obtained from the Munich Cancer Registry of the Munich Cancer Center or our clinical database. The patients from both cohorts (training set and validation set) were not treated on a specific clinical trial. Patient inclusion in the training and validation set of our study was only based on sample availability.
As we expected that gene expression profiles change over time as the disease progresses, we defined the time of molecular assessment as the starting time point for OS and TTT. Patient characteristics are shown in Table 1 and in more detail in Supplementary Table 1 . Patient data were anonymized before analysis. The retrospective study design was approved by the institutional review board of the medical faculty of the University of Munich.
The details of the microarray analysis and the development process of PS.8 are given in the supplement (see also Flow chart; Supplementary Figure 1) . In brief, we used a microarray data set of 151 CLL samples (44 Affymetrix HG-U133 A&B and 107 Affymetrix HG-U133 Plus 2.0 chips) to identify genes associated Abbreviations: CLL, chronic lymphocytic leukemia; Del., deletion; FISH, fluorescence in situ hybridization; OS, overall survival. a Note that 2 patients were analyzed twice at different disease stages and were considered as different samples due to disease evolution; the data therefore consist of 149 patients with 151 microarrays.
Letters to the Editor with OS. Then, a prognostic score (PS.8) was constructed based on the weighted expression levels of eight selected genes that performed best in the microarray and quantitative RT-PCR (qRT-PCR) assays following the procedure proposed by Bair and Tibshirani (supervised principal components approach). For validation, we measured the expression levels of the selected genes with qRT-PCR in 149 independent CLL patients. Univariate and multivariate Cox regressions were used to assess the effect of the score on survival. Prediction error curves were used to assess prediction quality. The microarray data set is accessible at Gene Expression Omnibus (GSE22762). The training and validation set had comparable distributions of genomic aberrations, the IGVH status, median white-cell and platelet counts, median hemoglobin levels, age, Binet stage, number of pretreatments, number and schedules of treatments and the median follow-up time. Significantly more patients with a VH3-21 rearrangement were present in the validation set and different pretreatment schedules were used in the groups (Table 1 and Supplementary Table 1 ). The prognostic eight gene based expression score (PS.8) was derived from the training set (Table 2) using the procedures described above (see also Flow chart; Supplementary Figure 1 ). PS.8 values of the 151 training microarrays were divided into three groups (high-, intermediate-, poor-risk group) using cutoffs at the 20th and 80th percentiles. Figure 1 demonstrates that PS.8 performs wellFas expectedFin the training data set. It is highly predictive (Po0.001) both for OS ( Figure 1a ) and TTT ( Figure 1b) . Additionally, using publicly available small, independent microarray data sets from CLL patients (GSE12734 from 14 patients and GSE4392 from 16 patients), we could show that our prognostic score performed surprisingly well in the classification of predefined risk groups (Supplementary Figure 2 ).
Quantitative RT-PCR for the eight genes of PS.8 was performed with cDNA samples from 149 independent CLL patients. The score was calculated using the weights derived from the training data. PS.8 predicted OS (Po0.001) and TTT (Po0.001) in the validation cohort. Representative KaplanMeier estimates for OS and TTT in patients with high (480 percentile), low (o20% percentile) and intermediate score values are shown in Figures 1c and d . Furthermore, PS.8 predicted OS (P ¼ 0.002) and TTT (Po0.001) in patients without previous treatments (Figures 1e and f) . The defined risk groups showed significant associations to markers of tumor burden (white blood cell count, Binet stage) and IGVH status and the deletion of 11q but not to other common genomic markers detected by FISH (Supplementary Table 2 ).
The performance of PS.8 was additionally evaluated in patient subgroups defined by known risk factors. Patients with mutated IGVH genes and no 17p13 or 11q23 deletions on FISH analysis represent patients with a favorable prognosis, whereas patients with unmutated IGVH genes or with a 17p13 or an 11q23 deletion have an unfavorable prognosis. PS.8 was able to significantly predict OS for the patients in the unfavorable prognosis group (P ¼ 0.01), but not in the favorable prognosis group (P ¼ 0.2). The latter result is most probably due to the weak power of the test caused by a low event rate (15%) Figures 2b and d. A total of 52 patients from our validation data set were defined as Binet A at time of first assessment. The mere four events in this group made comparisons of OS impossible. However, the analysis for TTT showed a significant effect of PS.8 in Binet A patients (P ¼ 0.01). Representative Kaplan-Meier curves are shown in Figure 2e . We did not analyze Binet stage B and C patients because these subgroups were too small. PS.8 was also predictive for the 59 newly diagnosed patients (OS P ¼ 0.02; TTT P ¼ 0.003). A representative Kaplan-Meier curve for OS in this group is shown in Figure 2f . Even though PS.8 was developed using gene expression data from unsorted PB mononuclear cells, the score was validated and performed well on expression data obtained from BM or PB irrespective of whether the cells had been sorted for CD19 positivity or not. Detailed results of univariate Cox regression for all subgroup analysis are given in the Supplementary Table 3. In the validation set, multivariate Cox regression models were fitted to OS and TTT using PS.8 (continuous), IGVH status, 17p13 deletion, 11q22-23 deletion, age (o 65 years vs X65 years) and sex as covariates. Binet stage was not included as covariate because of incomplete data. PS.8 had a highly significant association with both endpoints (Table 3) . For OS, 17p13 deletion, age and PS.8 were the only significant covariates. In the multivariate model for TTT, PS.8 is dominating all other covariates and is the only covariate significantly associated with TTT. Of note, the hazard ratio of PS.8 is given for one unit of change of the score (range of PS.8: À0.4 to þ 5.5). For example, an increase in the score from 1.5 to 2.5 results in a 1.92-fold increase in the risk for death (confidence interval (CI): 1.39-2.65). An increase of PS.8 from 1.5 to 3.5 increases the risk by 1.92 2 ( ¼ 3.69) and so on (CI: 1.93-7.02). Applied Biosystems low density array (LDA) primer.
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Subsequently, we excluded all pretreated patients and patients whose treatment status at analysis was unknown from these models. In this analysis, age, 17p-deletion and PS.8 again remained as the only significant covariates for OS, and PS.8 was the only significant covariate for TTT (Supplementary Table 4a ). In a multivariate model with PS.8 as categorized variable (using the cutoffs from Figure 1) Table 5a ). In this model PS.8 remains as significant covariate for OS and TTT. This is also the case for patients without previous treatments (Supplementary Table 5b ).
The additional predictive value of PS.8 was assessed using prediction error curves. For OS, a model solely based on PS.8 was superior to FISH and IGVH status as single markers and similar to the combined model of FISH and the IGVH status (Supplementary Figure 3a) . The model incorporating PS.8 as well as FISH and IGVH status performed best. For TTT, PS.8 was superior to the single parameters and also to a combined FISH and IGVH status model. The addition of FISH and IGVH status did not increase the performance of the prognostic score (Supplementary Figure 3b) . In summary, we correlated genome-wide micro array derived gene expression values with OS in a large and heterogeneous group of CLL patients. This approach resulted in the development of a score (PS.8) based on the expression levels of eight genes. The score was validated on a different technical platform (qRT-PCR) in an independent group of patients. Importantly, PS.8 showed additional prognostic value for OS and TTT compared with the established genetic markers. Specifically, PS.8 was able to add information in several subgroups defined by the established molecular markers and in Binet A patients. The analysis of the predictive performance using prediction error curves yielded superior performances for the models containing the prognostic score compared with the models based on FISH and IGVH status only. PS.8 was highly significant in the multivariate analysis of previously untreated patients. Despite the heterogeneous validation group and the time difference in sampling, the gene expression score could be validated in an independent patient cohort. PS.8 remained a prognostic marker in a multivariate analysis, which included the most powerful prognostic markers in CLL (FISH and IGVH). These data strongly indicated that PS.8 is a highly significant and valid risk predictor.
Several of the genes contained in PS.8 are likely to have an important role in the pathogenesis of CLL. For example, low expression levels of TCF7 (T cell specific, HMG box), a downstream target of the Wnt signaling pathway, were found in CLL patients with poor prognosis. Recently, Kienle et al.
7 also reported on the association of reduced TCF7 expression and poor outcome in CLL. The Wnt signaling pathway is activated in CLL, and our data strengthen the case for an important role of Wnt signaling in CLL. Low transcript levels of the phosphodiesterase 8A (PDE8A) were associated with poor prognosis in our CLL patients. A similar association was reported by Stamatopoulos et al., 8 who showed that PDE8A was part of a gene signature that distinguishes between ZAP70 positive and ZAP70 negative CLL samples. PDE8A might be connected to the NF-kB signaling pathway, which is frequently activated in lymphoid malignancies. Five genes in the score (MSI2, PLEKHA1, MGC29506, MGAT4A, SFTPB) have not been described in the context of CLL before. We show that high expression levels of MSI2 (musashi homolog 2) in CLL are associated with poor survival. MSI2 encodes an RNA-binding translational modulator that was recently shown to be a key regulator in the Musashi-Numb pathway and identified as a prognostic marker in chronic myelogenous leukemia.
9
MGC29506 (MZB1) is an endoplasmic reticulum-localized and B cell-specific protein that was very recently shown to be a key regulator of antibody secretion, integrin activation and calcium homeostasis. 10 It should be noted that genes like MSI2, MGC29506, MGAT4A and PLEKHA1 were not contained in older Affymetrix Arrays like the HGU95A chip that were used in previous studies on differential gene expression in CLL. Of note, two well-known prognostic gene expression markers in CLL, LPL and ZAP70, were not included in PS.8. It might be that the significance of ZAP70 was weakened by the use of unselected PB mononuclear cells for the microarray data set. The LPL expression level was a univariate significant parameter in both data sets (data not shown), but was excluded in subsequent selection steps.
The expression levels of the genes contained in PS.8 most probably reflect the status of several important cellular pathways, for example, the Wnt, NF-kB and Musashi-Numb signaling pathways. It is likely that PS.8 integrates and summarizes the activity of these pathways. In this context, it should be noted that treatment regimens are on the horizons that include selective pathway inhibitors targeting, for example, NF-kB or Wnt signaling.
Taken together, we present a powerful prognostic score for OS in CLL derived from a comprehensive gene expression analysis in a large cohort of patients. This score can be determined by measuring the expression levels of eight genes and can be easily implemented in a routine diagnostic setting. Prospective trials are now required to assess the relevance of PS.8 in comparison with the established genetic markers and to evaluate the usefulness of the score to guide individualized treatment choices. 
